Abstract
COVID-19 is now identified in almost all countries in the world, with poorer regions being particularly more disadvantaged to efficiently mitigate the impacts of the pandemic. In the absence of efficient therapeutics or vaccines, control strategies are currently based on non-pharmaceutical interventions, comprising changes in population behavior and governmental interventions, among which the prohibition of mass gatherings, closure of non-essential establishments, quarantine and movement restrictions. In this work we analyzed the effects of 547 published governmental interventions, and population adherence thereof, on the dynamics of COVID-19 cases across all 27 Brazilian states, with emphasis on state capitals and remaining inland cities. A generalized SEIR model with a time-varying transmission rate (TR), that considers transmission by asymptomatic individuals, is presented. Confirmed COVID-19 cases were used to calibrate the model parameters using non-linear least squares methods. We analyze the changes on the TR and effective reproduction number as a function of both the extent of enforced measures across Brazilian states as well as population movement. The social mobility reduction index, a measure of population movement, together with the stringency index, adapted to incorporate the degree of restrictions imposed by governmental regulations, were used in conjunction to quantify and compare the effects of varying degrees of policy strictness across Brazilian states. Our results show that population adherence to social distance recommendations plays an important role for the effectiveness of interventions, and represents a major challenge to the control of COVID-19 in low- and middle-income countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (CAPES), Finance Code 001. STRP was supported by an International Cooperation grant (process number \\ INT0002/2016) from Bahia Research Foundation (FAPESB). STRP and RFSA were supported by the National Institute of Science and Technology - Complex Systems from CNPq, Brazil. JFO was supported by the Center of Data and Knowledge Integration for Health (CIDACS) through the Zika Platform, a long term surveillance platform for Zika virus and microcephaly (Unified Health System (SUS), Brazilian Ministry of Health). DCJ acknowledges a Scientfic Initiation scholarship from CNPq (process number 117568/2019-8).MSS acknowledges a Scientific Initiation scholarship from CNPq (process number 116731/2019-2). The authors acknowledge the helpful suggestions from members of the CoVida Network (\url{http://covid19br.org}), in special to contributors to the Rede CoVida Modelling Task-force: Alan A. S. Amad, Arthur Rios, Aureliano S. S. Paiva, Caio P. Castro, Gabriela L. Borges, Gervasio F. Santos, Jose G. B. Castro, Jose G. V. Miranda, Maira L. Souza, Maria Yury Ichihara, Matheus F. Torquato, Mauricio L. Barreto, Raphael S. do Rosario, Rafael V. Veiga and Rosemeire L. Fiaconne. We acknowledge the InLoco team, namely Jose Luciano Melo, Raiza Oliveira, Afonso Delgado, Abel Borges, Andre De'Carli, Hector Pinheiro, Lucas Rufino, Gabriel Teotonio and Luiza Botelho for providing raw files of the Social mobility reduction data used here. We also acknowledge Brasil.io \url{https://brasil.io/datasets/}.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted with publicly available data from the COVID-19 epidemic, published by the Ministry of Health of Brazil or third parties. Therefore, no approval by an ethics committee was required, according to Resolutions 466/2012 and 510/2016 (article 1, sections III and V) from the National Health Council (CNS), Brazil.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Codes used to produce the results presented herein, and related datasets, are available as supplementary material and in a public GitHub repository.
https://github.com/cidacslab/Mathematical-and-Statistical-Modeling-of-COVID19-in-Brazil.git
